Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and innovative diagnostic solutions, today announced it will provide the Korean Red Cross (KRC) with its industry-leading Procleix Panther System running nucleic acid testing (NAT) technology to help ensure the safety of South Korea's blood supply.
By Sam Kerr
12.00 PM
Primafrio, the Spanish freight logistics company specialising in the refrigerated transportation of fruits and vegetables, has launched an IPO on the Spanish stock exchange.
The transaction will be a 100% secondary share placing sold by shareholders Juan and José Esteban Conesa, the company’s founders. The company is seeking a minimum 25% freefloat on the Spanish Stock Exchange.The transaction has been pilot-fished and investors are understood to be keen on an asset
. Already a subscriber? Login
Almirall receives FDA approval to produce Seysara® (sarecycline) at the Sant Andreu de la Barca (Barcelona) plant The production of this drug in Sant Andreu de la Barca (Barcelona) provides the company with a dual supply source and ensures the continuity of the business of this strategic productSeysara®.
Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis
Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) of the face or scalp and it acts through a selective antiproliferative mechanism of action
The positive opinion is based on the results from two pivotal phase III clinical trials which demonstrated complete clearance of AK lesions at day 57 in treated face or scalp areas in a significantly higher number of patients than with vehicle, together with a good safety and tolerability profile
With the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), tirbanibulin edges closer to European Commission approval, expected in approximately 60 days